Business · 27/05/2021Updated: 10/17/2026 · 1 min read

HHS Withdraws Notice on Unapproved Drugs Initiative and Ends Response Period

Summary

The Department of Health and Human Services (HHS) is withdrawing a notice and request for information regarding unapproved drugs that are potentially generally recognized as safe and effective, and also ending the response period for this notice.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Healthcare Business News Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News

Related business signals

Business · 9/16/2026

Agency Information Collection Request; 30-Day Public Comment Request

The Office of the Secretary (OS), Department of Health and Human Services, submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval, with a 30-day public comment period.

Read summary →

Business · 9/17/2026

Proposed Data Collection Activity for Diaper Distribution Demonstration and Research Pilot Beneficiary and Organizational Survey

The Administration for Children and Families, Department of Health and Human Services, is proposing to continue collecting data on diaper need and outcomes for beneficiaries of the Diaper Distribution Demonstration and Research Pilot, with proposed changes to the Beneficiary Survey and addition of an Organizational Survey.

Read summary →

Business · 9/15/2026

National Cancer Institute Considers Exclusive Patent License for Engineered Cell Therapies for HPV 16 E6-Expressing Cancers

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to MedGene Therapeutics, Inc., a Maryland-based company, to develop and commercialize engineered cell therapies for treating cancers caused by the HPV 16 E6 gene.

Read summary →

Business · 9/14/2026

Office of the National Coordinator for Health Information Technology; Health Information Technology Advisory Committee; Amended Notice of Meeting

The Office of the National Coordinator for Health Information Technology and the Health Information Technology Advisory Committee have issued an amended notice regarding a meeting, which appears to be a formal announcement of a scheduled event.

Read summary →

Business · 9/16/2026

Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Pathogen-Agnostic Sequencing

The Food and Drug Administration (FDA) announces a public advisory committee meeting of the Microbiology Devices Panel to discuss pathogen-agnostic sequencing for emergency preparedness and response efforts.

Read summary →

Business · 10/5/2026

CDC Invites Public Comment on Proposed Data Collection for Public Health Crisis Response

The Centers for Disease Control and Prevention (CDC) is seeking public feedback on a proposed data collection project, titled Public Health Crisis Response (PHCR) Cooperative Agreement, which aims to rapidly fund public health programs responding to major emergencies and crises, as required by the Paperwork Reduction Act of 1995.

Read summary →